Drug-induced liver injury (DILI) is one of the main causes of investigational new drug (IND) failure in clinic. At Aquila, we understand the importance of knowing the effects your test compounds or biologics have on hepatocytes early in discovery.
Hepatocytes play an essential role in toxin and drug metabolism and clearance. We use primary hepatocytes (human, rat or mouse) in our in vitro assays to predict drug hepatotoxicity. Our primary cell assay systems evaluate the impact of your drug candidate on hepatocyte proliferation, metabolism and enzyme activity.
We can tailor a study that meets your specific research needs. We can customise the experimental design to understand the MOA of your drug candidate. We work closely with you to build a stronger data package and speed up your route to clinic.
Get in touch today to discuss how we can help you predict the effects of your drug on the liver.